Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (1-10 of 230) with videos related to

Pageof 23
Sort By:
Transactions of the American Clinical and Climatological Association|June 21, 2011
Rational therapeutic options for patients with myeloproliferative neoplasmsRonald Hoffman
Seminars in Oncology|July 4, 2002
Quality of life issues in patients with essential thrombocythemia and polycythemia veraRonald Hoffman
The Mount Sinai Journal of Medicine, New York|November 25, 2010
Myeloproliferative neoplasms: new translational therapiesJohn Mascarenhas, Ronald Hoffman
The Lancet. Haematology|December 25, 2017
Don't judge a JAK2 inhibitor by spleen response aloneJohn Mascarenhas, Ronald Hoffman
Expert Opinion on Emerging Drugs|December 7, 2021
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trialsDouglas Tremblay, Ronald Hoffman
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2011
Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndromeSelcuk Sozer, Ronald Hoffman
Hematology. American Society of Hematology. Education Program|November 21, 2007
Biology and treatment of primary myelofibrosisRonald Hoffman, Damiano Rondelli
Oncotarget|November 21, 2012
p53 as a target in myeloproliferative neoplasmsMin Lu, Ronald Hoffman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosisJohn Mascarenhas, Ronald Hoffman
Frontiers in Oncology|June 1, 2022
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in MyelofibrosisLilian Varricchio, Ronald Hoffman
Pageof 23

Showing results (1-10 of 230) with videos related to

Sort By:
Pageof 23
Transactions of the American Clinical and Climatological Association|June 21, 2011
Rational therapeutic options for patients with myeloproliferative neoplasmsRonald Hoffman
Seminars in Oncology|July 4, 2002
Quality of life issues in patients with essential thrombocythemia and polycythemia veraRonald Hoffman
The Mount Sinai Journal of Medicine, New York|November 25, 2010
Myeloproliferative neoplasms: new translational therapiesJohn Mascarenhas, Ronald Hoffman
The Lancet. Haematology|December 25, 2017
Don't judge a JAK2 inhibitor by spleen response aloneJohn Mascarenhas, Ronald Hoffman
Expert Opinion on Emerging Drugs|December 7, 2021
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trialsDouglas Tremblay, Ronald Hoffman
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2011
Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndromeSelcuk Sozer, Ronald Hoffman
Hematology. American Society of Hematology. Education Program|November 21, 2007
Biology and treatment of primary myelofibrosisRonald Hoffman, Damiano Rondelli
Oncotarget|November 21, 2012
p53 as a target in myeloproliferative neoplasmsMin Lu, Ronald Hoffman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosisJohn Mascarenhas, Ronald Hoffman
Frontiers in Oncology|June 1, 2022
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in MyelofibrosisLilian Varricchio, Ronald Hoffman
Pageof 23